Hyderabad: Covaxin was developed with a focus Security First, then efficacy. This was the only COVID-19 vaccine In Indian government’COVID-19′ immunity Program to conduct efficacy trials in India. The vaccine was evaluated in more than 27,000 subjects as part of the licensing process.

It was licensed under restricted use clinical trials Mode, where detailed security reporting was done for several million subjects. The safety of Covaxin was also evaluated Ministry of Health, Indian government. ongoing security monitoring (pharmacovigilance) continued throughout the product life cycle of the vaccine.

All the above studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin, with no vaccine-related events of blood clots, thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc.

Bharat Biotech The team was well aware that, while the efficacy of COVID-19 vaccines may be short-lived, the impact on patient safety could last a lifetime. Therefore, safety is the primary focus for all our vaccines.